{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:59:21Z","timestamp":1790326761607,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005905","name":"Agence Fran\u00e7aise de Lutte contre le Dopage","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>Anti\u2010doping controls in non\u2010major events are relatively infrequent and athletes that compete only in these events are less likely to be controlled. The French Anti\u2010Doping Agency carried out an anti\u2010doping operation during a regional cycling competition in Guadeloupe. The urine and serum samples were analysed by the French anti\u2010doping laboratory. Out of 42 athletes, 7 were positive for one or more substances prohibited by the World Anti\u2010Doping Agency. Four serum samples contained continuous erythropoietin receptor activator (CERA) and one a recombinant erythropoietin. However, no traces were found in the corresponding urines. One of the athletes positive for CERA was also positive for growth hormone (GH), identified using the GH isoform test. The same serum was negative with the GH biomarkers test, probably because of the brief interval between injection and control (less than a day). The stimulants heptaminol and dimethylbutylamine, as well as the glucocorticoid prednisone and its metabolite prednisolone, were also found. Strikingly, 16.6% of the controlled athletes were using one or more prohibited drugs. These findings indicate that doping is widespread in athletes competing regionally and that CERA is still a popular drug for endurance sports. They underline the need for more controls, particularly blood sampling during non\u2010major competitions. Copyright \u00a9 2017 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.2185","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T03:33:24Z","timestamp":1489203204000},"page":"1753-1761","source":"Crossref","is-referenced-by-count":22,"title":["Report on an anti\u2010doping operation in Guadeloupe: High number of positive cases and inferences about doping habits"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-6939","authenticated-orcid":false,"given":"A.","family":"Marchand","sequence":"first","affiliation":[{"name":"Analysis Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buisson","sequence":"additional","affiliation":[{"name":"Analysis Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[{"name":"Analysis Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010A.","family":"Martin","sequence":"additional","affiliation":[{"name":"Analysis Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molina","sequence":"additional","affiliation":[{"name":"Analysis Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ressiot","sequence":"additional","affiliation":[{"name":"Control Department Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  8 rue Auber 75009 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-014-0247-x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.270"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2011.06.012"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2004"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.97"},{"key":"e_1_2_8_7_1","unstructured":"TD2004EPO.Harmonization of the method for the identification of epoetin alpha and beta (epo) and darbepoetin alfa (nesp) by ief\u2010double blotting and chemiluminescent detection v. 1.0 2004. Available at:www.wada\u2010ama.org."},{"key":"e_1_2_8_8_1","unstructured":"TD2015GH.Human growth hormone (hGH) isoform differential immunoassays for doping control analyses v. 1.0 2015. Available at:www.wada\u2010ama.org."},{"key":"e_1_2_8_9_1","unstructured":"Guidelines human growth hormone (hGH) biomarkers test for doping control analyses v. 2.0 2016. Available at:www.wada\u2010ama.org."},{"key":"e_1_2_8_10_1","unstructured":"TD2014EPO.Harmonization of analysis and reporting of erythropoiesis stimulating agents (ESAs) by electrophoretic techniques v. 1.0 2014. Available at:www.wada\u2010ama.org."},{"key":"e_1_2_8_11_1","unstructured":"TD2016EAAS.Technical document for endogenous anabolic androgenic steroids v. 1.0 2015. Available at:www.wada\u2010ama.org"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00730306"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.6692"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.006809"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2010.195917"},{"key":"e_1_2_8_16_1","first-page":"253","volume-title":"Recent Advances in Doping Analysis","author":"Reihlen P.","year":"2013"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu089"},{"key":"e_1_2_8_18_1","first-page":"99","article-title":"Growth hormone doping: a review","volume":"2","author":"Erotokritou\u2010Mulligan I.","year":"2011","journal-title":"Open Access J. Sports Med."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2013.01.002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1123\/jsep.29.3.382"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.1677"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1735"},{"key":"e_1_2_8_23_1","unstructured":"Anti\u2010Doping Testing Figures Report. Testing Authority Report 2014. Available at:www.wada\u2010ama.org."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.2185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:42:55Z","timestamp":1760377375000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":22,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/dta.2185"],"URL":"https:\/\/doi.org\/10.1002\/dta.2185","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]}}}